We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
- Authors
Punglia, Rinaa S; Burstein, Harold J; Winer, Eric P; Weeks, Jane C
- Abstract
Adjuvant endocrine treatment with aromatase inhibitors improves disease-free survival compared with tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer. This difference could be due to differences in tamoxifen metabolism because levels of endoxifen, the active tamoxifen metabolite, vary with the number of mutant alleles, including the *4 allele, of the gene encoding cytochrome P450 2D6 (CYP2D6).
- Publication
Journal of the National Cancer Institute, 2008, Vol 100, Issue 9, p642
- ISSN
1460-2105
- Publication type
Journal Article
- DOI
10.1093/jnci/djn100